

# Understanding myasthenia gravis

Myasthenia gravis (MG) is a chronic autoimmune disease characterized by fluctuating muscle weakness. In MG, the body's immune system attacks the connections between nerves and muscles, causing weakness and fatigue in muscles under your voluntary control.<sup>1,2</sup>

**Symptoms often emerge in the eyes:<sup>1,2</sup>**



Drooping eyelids



Blurred or double vision

**In more advanced MG, symptoms progress into the face, throat and limbs:<sup>1,2</sup>**



Change in facial expression




Difficulty chewing or swallowing



Impaired speech



Weakness of arms, hands or legs



Difficulty breathing



Profound tiredness

**MG is unpredictable, and often requires lifestyle modifications for people to engage in everyday activities.<sup>3</sup>**


"With MG, you learn to embrace and plan for uncertainty. It's a constant battle to figure out what your body needs."

— Jonni, living with MG

## Burden of MG Management

MG is a chronic illness with most people requiring lifelong therapy.<sup>4</sup>

Yet, current treatments do not fully address patient needs. Limitations include:<sup>5</sup>



Episodic or  
cyclical  
treatments



Prolonged  
time to onset  
of effect



Fear of  
disease flares



Safety and  
side effects



Invasive and /  
or burdensome  
routes of  
administration

## A New Approach to Treatment<sup>6</sup>

At Immunovant, we're developing anti-FcRn technology that may reduce harmful IgG autoantibodies with tailored dosing, to help alleviate symptoms across disease stage and severity. Our aim is:



**Rapid and deep IgG reduction** to gain initial disease control



**Maintenance dosing** for sustainable control with potentially fewer side effects



**Tailored dosing** to address varying symptoms and disease fluctuations



**Subcutaneous injection** to enable self-administration at home

IgG = immunoglobulin G

### References:

1. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis. Available at: <https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis>. Accessed October 16, 2023. 2. Myasthenia Gravis Foundation of America. Autoimmune Myasthenia Gravis brochure. Available at <https://myasthenia.org/MG-Education/Learn-More-About-MG-Treatments/MG-Brochures>. Accessed October 16, 2023. 3. MG Patient Quantitative Survey (n=50) Q: What is the extent of lifestyle modifications you make around your myasthenia gravis? 4. Drachman, D. Myasthenia Gravis. Semin Neurol. 2016 Oct; 36(5):419-424. 5. Market research data on file at Immunovant. 6. Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis; NCT05403541. Available at: <https://clinicaltrials.gov/ct2/show/NCT05403541?term=batoclimab&draw=2&rank=1>. Accessed October 16, 2023.